Recursion Advances Neuroscience Target with Genentech as Pipeline Progresses — Recursion Pharmaceuticals, Inc.

Event summary

Genentech exercised its first Validated Target Option under the neuroscience collaboration, advancing a previously unexplored target into an early discovery program.
Recursion reduced its 2026 cash operating expense guidance to <$375 million from <$390 million.
REC-4881 (MEK1/2 inhibitor) Phase 2 data will be presented at the CGA-IGC Annual Meeting in November 2026.
REC-7735 (PI3Kα H1047R inhibitor) IND cleared, with Phase 1/2 trial initiation expected in 2H26.

The big picture

Recursion's advancement of a neuroscience target with Genentech underscores the strategic value of its AI-native platform in uncovering novel therapeutic opportunities. The company's ability to reduce operating expenses while progressing multiple clinical programs highlights its focus on financial discipline amid a competitive biotech landscape. The scale of potential milestone payments from key partnerships positions Recursion for significant growth if its pipeline delivers.

What we're watching

Pipeline Execution: The pace at which Recursion can advance its internal pipeline, particularly REC-4881 and REC-7735, will be critical for validating its AI-native platform.
Financial Discipline: Whether Recursion can sustain reduced operating expenses while maintaining aggressive R&D efforts will impact its cash runway into early 2028.
Collaboration Milestones: The potential for additional milestone payments from partnerships with Genentech, Roche, and Sanofi could significantly boost Recursion's financial position.